- Relocation from Izunokuni City to Shonan iPark is set for January 2027.
- Shonan iPark offers a globally connected life-science ecosystem.
- Focus areas include autoimmune diseases, severe infectious diseases, transplantation, and renal diseases.
- The new location will feature state-of-the-art open labs and shared equipment.
Relocation Plans
Asahi Kasei Pharma plans to move its R&D hub from Izunokuni City, Shizuoka Prefecture, to Shonan Health Innovation Park (Shonan iPark) in January 2027. This relocation aims to enhance the company's global R&D capabilities and foster open innovation through collaboration with external partners.
Strategic Location
Shonan iPark was chosen for its globally connected life-science ecosystem, which includes pharmaceutical companies, next-generation medicine, AI/digital health, venture capital, and academia. The area is a developing hub for young and advanced professionals, expected to attract outstanding R&D talent.
Focus Areas
Asahi Kasei Pharma will concentrate on autoimmune diseases, severe infectious diseases, transplantation, and renal diseases. The new location will feature state-of-the-art open labs and shared equipment, improving research investment efficiency and accelerating operations.
Future Outlook
The relocation is expected to expedite the creation of breakthrough new medicines and facilitate the market introduction of developed pharmaceuticals. Asahi Kasei has identified Pharmaceuticals as a First Priority business in its medium-term management plan, aiming to integrate drug discovery expertise with cutting-edge technologies.
